Skip to content
新闻中心
关于我们 职业生涯 新闻中心 联系我们 法务 iHope 与Illumina合作 投资者 支持抗击COVID-19 Illumina for Startups Home

新闻稿

因美纳发布2021财年第二季度的业绩报告

2021-8-5

上调2021财年业绩指导

美国加利福尼亚州圣迭戈——2021年8月5日，因美纳公司（纳斯达克股票代码：ILMN）宣布2021财年第二季度的财务业绩。

第二季度业绩取得了创纪录的增长：

  • 收入11.26亿美元，较去年同期增长78%
  • 按一般公认会计原则（GAAP）测算，第二季度净收入1.85亿美元（摊薄每股收益为1.26美元），去年同期为4,700万美元（摊薄每股收益为0.32美元）
  • 第二季度非GAAP净收入为2.76亿美元（摊薄每股收益1.87美元），去年同期为9,200万美元（摊薄每股收益为0.62美元）。非GAAP净收入不包括收购相关开支，主要是支付给GRAIL的后续付款
  • 运营现金流为2.53亿美元，去年同期为2.4亿美元
  • 第二季度的自由现金流（运营现金流减去资本支出）为2.09亿美元，去年同期为2.02亿美元

“因美纳第二季度创纪录的收入超过了此前所有业务地区的预期，”因美纳首席执行官Francis deSouza说道，“这展现了我们在临床应用和科研，包括肿瘤、遗传病检测等领域的强劲实力。此外，NGS技术在识别和监测新冠变异，以制定应对疫情的策略方面发挥了重要作用，为此我们倍感骄傲。由于核心业务的持续强劲发展，我们将再次上调2021财年的业绩指导。”

2021年第二季度的毛利率为71.2%，去年同期为67.7%。除去购得的无形资产的摊销，2021年第二季度的非GAAP毛利率为71.8%，去年同期为68.6%。

2021年第二季度的研发费用为2.02亿美元，去年同期为1.55亿美元。非GAAP研发开支占收入百分比为18.0%，去年同期为24.7%。

2021年第二季度的销售、一般和行政 (SG&A) 开支为4.13亿美元，去年同期为1.77亿美元。不计收购相关开支、诉讼收益以及新冠疫情相关开支和收入，非GAAP SG&A费用占收入百分比为23.8%，去年同期为28.1%。

在2021年第二季度，折旧和摊销开支为4,800万美元，自由现金流的资本支出为4,400万美元。截至本季度末，公司持有43亿美元的现金、现金等价物和短期投资，截至2021年1月3日为35亿美元。

自上次业绩报告发布以来的更新信息：

  • 与比尔及梅琳达·盖茨基金会合作发起了一项全球病原体基因组学计划，旨在帮助需要的地区获取测序技术和专业知识，构建关键的公共卫生管理能力，推动公共卫生体系在应对生物威胁方式上的革命性发展
  • 应用于NextSeq™ 2000平台的COVIDSeq™检测获得了美国食品药品监督管理局 (FDA) 的紧急使用授权，拓展了中高通量实验室的新冠病毒诊断检测和监测能力
  • 与Next Generation Genomic Co., Ltd.携手在泰国推出CE-IVD VeriSeq NIPT Solution v2，提升准父母获得准确可靠的产前检测的机会
  • NextSeq™ 1000/2000 基因测序平台荣获2021年红点设计大奖，充分证明了其卓越的设计品质
  • 在上海主办首届NGS峰会，超过300余名基因测序领域科学家、投资者和医院管理者等汇聚一堂，共同探讨肿瘤领域和医疗行业的未来
  • 任命Susan Tousi为首席商务官，Alex Aravanis博士为首席技术官、研究和产品开发主管

财务预期和指导

下文讨论的非GAAP财务指导反映了某些预估调整，以协助分析和评估我们的核心运营绩效。

对于2021财年，公司目前预计收入同比增长32%至34%，GAAP摊薄每股收益为4.69美元至4.89美元，非GAAP摊薄每股收益为6.3美元至6.5美元。公司的财务指导不包括合并GRAIL财务业绩的任何潜在影响。

电话会议信息

电话会议于2021年8月5日星期四太平洋时间下午2:00（美国东部时间下午5:00）开始。如有兴趣，请访问因美纳网站www.illumina.com.cn“公司”选项卡下的“投资者信息”板块收听直播电话会议。或者，北美以外的个人可以使用会议ID 2850779拨打1 (866) 211-4597或1 (647) 689-6853收听。

活动结束后，因美纳网站将提供电话会议重播，并保留30天。

关于使用非GAAP财务指标的声明

公司报告的非GAAP业绩，包括摊薄每股净收益、净收益、毛利率、运营开支、营业毛利、其他收益，以及作为GAAP财务指标补充（并非代替或优于财务指标）的自由现金流量。公司的GAAP财务指标包括大量费用，例如购得的无形资产的摊销、公司可转换债务工具相关的非现金利息支出（可现金结算），以及GAAP和非GAAP之间的对帐中所列的其他开支。管理层已在非GAAP指标中排除这些项目的影响，以帮助投资者分析和评估过去和未来的运营业绩。此外，非GAAP净收入和摊薄每股收益是公司董事会用于衡量管理层绩效并确定管理层薪酬重要要素的一些财务指标中的关键组成部分。

公司鼓励投资者仔细考虑其GAAP业绩、其非GAAP补充信息以及此类业绩之间的对帐，确保更全面地了解其业务。

前瞻性声明

本新闻稿包含涉及风险和不确定性的前瞻性陈述。可能导致实际结果与任何前瞻性陈述产生重大差异的重要因素包括：(i)新冠疫情对我们业务与运营结果的影响；(ii)我们所服务市场的增长率变化；(iii)我们产品和服务相关的客户订单数量、时间和组合情况；(iv)我们依照我们收入预期来调整运营开支的能力；(v)GRAIL, Inc.收购计划的相关结果；(vi)我们生产优质仪器和耗材的能力；(vii)与我们竞争的产品和服务是否成功；(viii)开发、制造和推出新产品和服务本身所面临的挑战，包括扩大或修改制造业务，以及依赖第三方供应商提供关键部件；(ix)最近推出或预先公布的产品和服务对现有产品和服务的影响；(x)我们进一步开发并商业化仪器和耗材的能力，以及针对我们技术平台部署新产品、服务和应用以及拓展市场的能力；(xi)我们从政府机构获得产品监管许可的能力；(xii)我们与其他公司和组织成功合作开发新产品、拓展市场和发展业务的能力；(xiii)我们成功识别和整合收购技术、产品或业务的能力；(xiv)普遍接受的会计原则的应用（这些原则非常复杂，涉及许多主观假设、估计和判断），以及我们在提交给美国证券交易委员会的文件中所详细说明的其他因素，包括我们最近填写的10-K和10-Q表格，或者在公开电话会议（其日期和时间已于之前发布）上披露的信息。我们没有义务也不打算更新这些前瞻性声明，亦不会评估或确认分析师的相关预期，提供当季度的中期报告或更新文件。

关于因美纳

因美纳公司致力于推动和激发基因组学的发展而不断改善人类健康。专注创新使我们成为全球基因测序和芯片技术的领导者，并为全球范围的科研、临床和应用市场客户提供专业服务。我们的产品广泛应用于生命科学、肿瘤学、生殖保健、农业及其他新兴领域。欲了解更多信息，请访问www.illumina.com.cn或关注因美纳微信公众号。

投资者关系:
Brian Blanchett
+1.858.291.6421
ir@illumina.com

媒体:
Dr. Karen Birmingham
+1.646.355.2111
kbirmingham@illumina.com

 

Illumina, Inc.
 Condensed Consolidated Balance Sheets
 (In millions)

 
 

July 4,
2021

 

January 3,
2021

ASSETS

(unaudited)

   

Current assets:

      

Cash and cash equivalents

$

4,196

   

$

1,810

  

Short-term investments

90

   

1,662

  

Accounts receivable, net

540

   

487

  

Inventory

380

   

372

  

Prepaid expenses and other current assets

104

   

152

  

Total current assets

5,310

   

4,483

  

Property and equipment, net

915

   

922

  

Operating lease right-of-use assets

566

   

532

  

Goodwill

966

   

897

  

Intangible assets, net

162

   

142

  

Other assets

756

   

609

  

Total assets

$

8,675

   

$

7,585

  
       

LIABILITIES AND STOCKHOLDERS' EQUITY

     

Current liabilities:

      

Accounts payable

$

200

   

$

192

  

Accrued liabilities

674

   

541

  

Convertible senior notes, current portion

—

   

511

  

Total current liabilities

874

   

1,244

  

Operating lease liabilities

704

   

671

  

Term notes

992

   

—

  

Convertible senior notes

687

   

673

  

Other long-term liabilities

238

   

303

  

Stockholders' equity

5,180

   

4,694

  

Total liabilities and stockholders' equity

$

8,675

   

$

7,585

  

 

 

Illumina, Inc.
C ondensed Consolidated Statements of Income
 (In millions, except per share amounts)
 (unaudited)

 
 

Three Months Ended

 

Six Months Ended

 

July 4,
2021

 

June 28,
2020

 

July 4,
2021

 

June 28,
2020

Revenue:

              

Product revenue

$

972

   

$

527

    

$

1,925

   

$

1,228

  

Service and other revenue

154

   

106

    

294

   

264

  

Total revenue

1,126

   

633

    

2,219

   

1,492

  

Cost of revenue:

              

Cost of product revenue (a)

254

   

152

    

519

   

326

  

Cost of service and other revenue (a)

63

   

46

    

121

   

105

  

Amortization of acquired intangible assets

7

   

7

    

13

   

14

  

Total cost of revenue

324

   

205

    

653

   

445

  

Gross profit

802

   

428

    

1,566

   

1,047

  

Operating expense:

              

Research and development (a)

202

   

155

    

398

   

311

  

Selling, general and administrative (a)

413

   

177

    

787

   

451

  

Total operating expense

615

   

332

    

1,185

   

762

  

Income from operations

187

   

96

    

381

   

285

  

Other income (expense), net

20

   

69

    

(3)

   

57

  

Income before income taxes

207

   

165

    

378

   

342

  

Provision for income taxes

22

   

118

    

45

   

122

  

Net income

$

185

   

$

47

    

$

333

   

$

220

  

Earnings per share:

              

Basic

$

1.27

   

$

0.32

    

$

2.28

   

$

1.50

  

Diluted

$

1.26

   

$

0.32

    

$

2.26

   

$

1.49

  

Shares used in computing earnings per common share:

              

Basic

146

   

147

    

146

   

147

  

Diluted

147

   

148

    

147

   

148

  
 

(a) Includes stock-based compensation expense for stock-based awards:
 
 

Three Months Ended

 

Six Months Ended

 

July 4,
2021

 

June 28,
2020

 

July 4,
2021

 

June 28,
2020

Cost of product revenue

$

8

   

$

3

    

$

15

   

$

7

  

Cost of service and other revenue

1

   

1

    

2

   

2

  

Research and development

26

   

12

    

50

   

27

  

Selling, general and administrative

45

   

1

    

80

   

19

  

Stock-based compensation expense before taxes

$

80

   

$

17

    

$

147

   

$

55

  

 

 

Illumina, Inc.
 Condensed Consolidated Statements of Cash Flows
 (In millions)
 (unaudited)

 
 

Three Months Ended

 

Six Months Ended

 

July 4,
2021

 

June 28,
2020

 

July 4,
2021

 

June 28,
2020

Net cash provided by operating activities

$

253

   

$

240

    

$

535

   

$

521

  

Net cash provided by (used in) investing activities

3

   

(320)

    

1,379

   

(455)

  

Net cash (used in) provided by financing activities

(496)

   

(143)

    

472

   

(334)

  

Effect of exchange rate changes on cash and cash equivalents

3

   

2

    

—

   

(4)

  

Net (decrease) increase in cash and cash equivalents

(237)

   

(221)

    

2,386

   

(272)

  

Cash and cash equivalents, beginning of period

4,433

   

1,991

    

1,810

   

2,042

  

Cash and cash equivalents, end of period

$

4,196

   

$

1,770

    

$

4,196

   

$

1,770

  
               

Calculation of free cash flow:

              

Net cash provided by operating activities

$

253

   

$

240

    

$

535

   

$

521

  

Purchases of property and equipment

(44)

   

(38)

    

(86)

   

(79)

  

Free cash flow (a)

$

209

   

$

202

    

$

449

   

$

442

  
   

(a)

Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies.

 

 

Illumina, Inc.
 Results of Operations - Non-GAAP
 (In millions, except per share amounts)
 (unaudited)

 

RECONCILIATION BETWEEN GAAP AND NON-GAAP EARNINGS PER SHARE:

 
 

Three Months Ended

 

Six Months Ended

 

July 4,
2021

 

June 28,
2020

 

July 4,
2021

 

June 28,
2020

GAAP earnings per share - diluted

$

1.26

   

$

0.32

    

$

2.26

   

$

1.49

  

Cost of revenue (b)

0.05

   

0.04

    

0.10

   

0.09

  

Research and development costs (b)

—

   

(0.01)

    

—

   

(0.02)

  

Selling, general and administrative costs (b)

0.98

   

(0.01)

    

2.01

   

0.62

  

Other income, net (b)

(0.16)

   

(0.38)

    

(0.02)

   

(0.29)

  

Incremental non-GAAP tax expense (c)

(0.25)

   

0.07

    

(0.55)

   

(0.13)

  

Income tax benefit (d)

(0.01)

   

(0.02)

    

(0.04)

   

(0.11)

  

Tax expense related to increase in valuation allowance (e)

—

   

0.42

    

—

   

0.42

  

Tax expense related to cost-sharing arrangement (f)

—

   

0.19

    

—

   

0.19

  

Non-GAAP earnings per share - diluted (a)

$

1.87

   

$

0.62

    

$

3.76

   

$

2.26

  
 

RECONCILIATION BETWEEN GAAP AND NON-GAAP NET INCOME:

 
 

Three Months Ended

 

Six Months Ended

 

July 4,
2021

 

June 28,
2020

 

July 4,
2021

 

June 28,
2020

GAAP net income

$

185

   

$

47

    

$

333

   

$

220

  

Cost of revenue (b)

7

   

6

    

14

   

14

  

Research and development costs (b)

—

   

(1)

    

—

   

(2)

  

Selling, general and administrative costs (b)

144

   

(1)

    

295

   

92

  

Other income, net (b)

(22)

   

(56)

    

(2)

   

(43)

  

Incremental non-GAAP tax expense (c)

(36)

   

10

    

(80)

   

(19)

  

Income tax benefit (d)

(2)

   

(3)

    

(6)

   

(17)

  

Tax expense related to increase in valuation allowance (e)

—

   

62

    

—

   

62

  

Tax expense related to cost-sharing arrangement (f)

—

   

28

    

—

   

28

  

Non-GAAP net income (a)

$

276

   

$

92

    

$

554

   

$

335

  
 

All amounts in tables are rounded to the nearest millions, except as otherwise noted.  As a result, certain amounts may not recalculate using the rounded amounts provided.
   

(a)

Non-GAAP net income and diluted earnings per share exclude the effect of the pro forma adjustments as detailed above. Non-GAAP net income and diluted earnings per share are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance.

(b)

Refer to our "Itemized Reconciliation between GAAP and Non-GAAP Results of Operations as a Percent of Revenue," below, for the components of these amounts.

(c)

Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.

(d) 

Amounts represent tax deductions taken in excess of stock-based compensation cost.

(e) 

Amounts represent discrete tax expense related to the valuation allowance established in Q2 2020 against the deferred tax asset for California research and development credits.

(f)

Amounts represent discrete tax expense related to the finalization of the Altera court case in Q2 2020 which determined stock-based compensation must be included in intercompany cost sharing payments.

 

 

Illumina, Inc.
 Results of Operations - Non-GAAP (continued)
 (Dollars in millions)
 (unaudited)

 

ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE:

 
 

Three Months Ended

 

Six Months Ended

 

July 4,
2021

 

June 28,
2020

 

July 4,
2021

 

June 28,
2020

GAAP gross profit (b)

$

802

 

71.2

%

 

$

428

  

67.7

%

  

$

1,566

70.6

%

 

$

1,047

  

70.2

%

Amortization of acquired intangible assets

7

 

0.6

%

 

7

  

1.0

%

  

13

 

0.6

%

 

14

  

0.9

%

Expenses related to COVID-19 (c)

—

 

—

   

1

  

0.2

%

  

1

 

—

   

2

  

0.1

%

Income related to COVID-19 (d)

—

 

—

   

(2)

  

(0.3)

%

  

—

 

—

   

(3)

  

(0.2)

%

Restructuring (e)

—

 

—

   

—

  

—

    

—

 

—

   

1

  

0.1

%

Non-GAAP gross profit (a)

$

809

 

71.8

%

 

$

434

  

68.6

%

  

$

1,580

 

71.2

%

 

$

1,061

  

71.1

%
                       

GAAP research and development expense

$

202

 

18.0

%

 

$

155

  

24.5

%

  

$

398

 

18.0

%

 

$

311

  

20.8

%

Income related to COVID-19 (d)

—

 

—

   

1

  

0.2

%

  

—

 

—

   

2

  

0.1

%

Non-GAAP research and development expense

$

202

 

18.0

%

 

$

156

  

24.7

%

  

$

398

 

18.0

%

 

$

313

  

20.9

%
                       

GAAP selling, general and administrative expense

$

413

 

36.6

%

 

$

177

  

28.0

%

  

$

787

 

35.4

%

 

$

451

  

30.3

%

Amortization of acquired intangible assets

—

 

—

   

—

  

—

    

(1)

 

—

   

(1)

  

(0.1)

%

Acquisition-related expenses (f)

(145)

 

(13.0)

%

 

(1)

  

(0.2)

%

  

(295)

 

(13.3)

%

 

(93)

  

(6.2)

%

Expenses related to COVID-19 (c)

(1)

 

—

   

(2)

  

(0.3)

%

  

(2)

 

(0.1)

%

 

(2)

  

(0.1)

%

Income related to COVID-19 (d)

—

 

—

   

2

  

0.3

%

  

1

 

—

   

2

  

0.1

%

Gain on litigation (g)

2

 

0.2

%

 

—

  

—

    

2

 

0.1

%

 

—

  

—

  

Restructuring (e)

—

 

—

   

2

  

0.3

%

  

—

 

—

   

2

  

0.1

%

Non-GAAP selling, general and administrative expense

$

269

 

23.8

%

 

$

178

  

28.1

%

  

$

492

 

22.1

%

 

$

359

  

24.1

%
                       

GAAP operating profit

$

187

 

16.6

%

 

$

96

  

15.2

%

  

$

381

 

17.2

%

 

$

285

  

19.1

%

Cost of revenue

7

 

0.6

%

 

6

  

0.9

%

  

14

 

0.6

%

 

14

  

0.9

%

Research and development costs

—

 

—

   

(1)

  

(0.2)

%

  

—

 

—

   

(2)

  

(0.1)

%

Selling, general and administrative costs

144

 

12.8

%

 

(1)

  

(0.1)

%

  

295

 

13.3

%

 

92

  

6.2

%

Non-GAAP operating profit (a)

$

338

 

30.0

%

 

$

100

  

15.8

%

  

$

690

 

31.1

%

 

$

389

  

26.1

%
                       

GAAP other income (expense), net

$

20

 

1.8

%

 

$

69

  

10.8

%

  

$

(3)

 

(0.2)

%

 

$

57

  

3.8

%

Non-cash interest expense (h)

10

 

0.9

%

 

10

  

1.7

%

  

20

 

1.0

%

 

21

  

1.4

%

Strategic investment related (gain) loss, net (i)

(25)

 

(2.2)

%

 

(69)

  

(10.8)

%

  

14

 

0.7

%

 

(74)

  

(5.0)

%

Loss (gain) on derivative assets (j)

—

 

—

   

11

  

1.7

%

  

(26)

 

(1.2)

%

 

15

  

1.0

%

Bridge facility fees (k)

—

 

—

   

—

  

—

    

7

 

0.3

%

 

—

  

—

  

Gain on contingent value right (l)

(8)

 

(0.7)

%

 

(8)

  

(1.3)

%

  

(18)

 

(0.8)

%

 

(5)

  

(0.3)

%

Loss on extinguishment of debt (m)

1

 

—

   

—

  

—

    

1

 

—

   

—

  

—

  

Non-GAAP other (expense) income, net (a)

$

(2)

 

(0.2)

%

 

$

13

  

2.1

%

  

$

(5)

 

(0.2)

%

 

$

14

  

0.9

%
 

All amounts in tables are rounded to the nearest millions, except as otherwise noted.  As a result, certain amounts may not recalculate using the rounded amounts provided.

(a)

Non-GAAP gross profit, included within non-GAAP operating profit, is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of our products and services. Non-GAAP operating profit, and non-GAAP other (expense) income, net, exclude the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance.

(b)

Reconciling amounts are recorded in cost of revenue.

(c)

Amounts consist of direct and incremental expenses incurred due to the COVID-19 pandemic, primarily expenses related to employee testing and incremental cleaning in 2021, and personal protective equipment and premium pay for onsite essential workers in 2020.

(d) 

Amounts consist of direct and incremental income due to the COVID-19 pandemic, primarily payroll-related credits earned in the US and Canada in Q1 2021, and payroll-related credits earned in Singapore in 2020.

(e)

Amount consists primarily of employee costs, net of adjustments, related to restructuring in 2020. 

(f)

Amounts for Q2 2021 and the first half of 2021 consist primarily of expenses related to the pending acquisition of GRAIL, including $105 million in Continuation Payments paid during both Q1 and Q2 2021. Amount for the first half of 2020 consists primarily of expenses related to the Continuation Advances and Reverse Termination Fee paid to Pacific Biosciences related to the terminated acquisition.

(g)

Amount consists of a gain related to a patent litigation settlement.

(h)

Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(i) 

Amounts consist primarily of mark-to-market adjustments and impairments from our strategic investments.

(j)

Amount for the first half of 2021 consists of a gain recorded on our derivative assets related to the terminated acquisition with Pacific Biosciences as a result of Pacific Biosciences repaying to us $52 million in Continuation Advances.  Amounts for Q2 2020 and the first half of 2020 consist of fair value adjustments recorded on our derivative assets.

(k)

Amount consists of expenses related to the bridge facility commitment obtained in advance of the pending acquisition of GRAIL.  We terminated the bridge facility commitment in March 2021, in conjunction with our issuance of term notes.

(l)

Amounts consist of fair value adjustments related to our contingent value right received from Helix.

(m) 

Amount consists of loss on extinguishment of our 2021 Convertible Senior Notes, which matured in June 2021.

 

Illumina, Inc.
 Reconciliation of Non-GAAP Financial Guidance
 (unaudited)

 

Our future performance and financial results are subject to risks and uncertainties, and actual results could differ
materially from the guidance set forth below. Some of the factors that could affect our financial results are stated above
in this press release. More information on potential factors that could affect our financial results is included from time to
time in the public reports filed with the Securities and Exchange Commission, including Form 10-K for the fiscal year
ended January 3, 2021 filed with the SEC on February 17, 2021, and Form 10-Q for the fiscal quarter ended April 4,
2021. We assume no obligation to update any forward-looking statements or information.
 
 

Fiscal Year

2021

GAAP diluted earnings per share (a)

$4.69 - $4.89

Amortization of acquired intangible assets

0.18

Non-cash interest expense (b)

0.24

Acquisition-related expenses (c)

1.99

Strategic investment related loss, net (d)

0.09

Bridge facility fees (e)

0.05

COVID-19 expenses, net (f)

0.01

Loss on extinguishment of debt (g)

0.01

Gain on derivative assets (h)

(0.18)

Gain on contingent value right (i)

(0.12)

Gain on litigation (j)

(0.01)

Incremental non-GAAP tax expense (k)

(0.61)

Excess tax benefits from share-based compensation (l)

(0.04)

Non-GAAP diluted earnings per share (a)

$6.30 - $6.50
 

(a)

Guidance excludes any potential impact of consolidating the financial results of GRAIL.

(b)

Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(c)

Amount consists primarily of acquisition-related expenses related to the pending acquisition of GRAIL.

(d)

Amount consists primarily of mark-to-market adjustments and impairments from our strategic investments.

(e) 

Amount consists of expenses related to the bridge facility commitment obtained in advance of the pending acquisition of GRAIL.  We terminated the bridge facility commitment in March 2021, in conjunction with our issuance of term notes.

(f)

Amount consists of direct and incremental expenses incurred due to the COVID-19 pandemic, primarily expenses related to employee testing and incremental cleaning, partially offset by direct and incremental income due to the COVID-19 pandemic, primarily payroll-related credits earned in the US and Canada.

(g)

Amount consists of loss on extinguishment of our 2021 Convertible Senior Notes, which matured in June 2021.

(h)

Amount consists of gain recorded on our derivative assets related to the terminated acquisition with Pacific Biosciences as a result of Pacific Biosciences repaying to us $52 million in Continuation Advances.

(i)

Amount consists of fair value adjustments related to our contingent value right received from Helix.

(j)

Amount consists of a gain related to a patent litigation settlement.

(k)

Incremental non-GAAP tax expense reflects the tax impact related to the non-GAAP adjustments listed.

(l)

Amount represents tax deductions taken in excess of stock-based compensation cost.

 

CisionView original content:https://www.prnewswire.com/news-releases/illumina-reports-financial-results-for-second-quarter-of-fiscal-year-2021-301349740.html

SOURCE Illumina, Inc.

 

上一篇文章
下一篇文章

Recent Articles

开拓农业基因组学研究与保护之路
开拓农业基因组学研究与保护之路
鲜为人知的基因组学应用：减轻奶牛打嗝强度
鲜为人知的基因组学应用：减轻奶牛打嗝强度
Nucleus Genomics致力推动个性化医疗成为现实
Nucleus Genomics致力推动个性化医疗成为现实

仅供研究使用。不得用于诊断。（除特殊标注外）

创新技术

在Illumina，我们的目标是应用创新技术来分析遗传变异和功能，实现几年前甚至还无法想象的研究。我们的任务是提供创新、灵活、可扩展的解决方案以满足客户的需求。作为一家重视合作互动、快速交付解决方案和提供高质量水平的全球性公司，我们努力应对这一挑战。Illumina创新的测序和芯片技术正在推动生命科学研究、转化和消费者基因组学以及分子诊断中的进展。

所有商标均为 Illumina 公司或其各自所有者的财产。
具体商标信息，请参见 www.illumina.com.cn/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.